LL 067

Drug Profile

LL 067

Alternative Names: LL-067

Latest Information Update: 08 Jan 2016

Price : $50

At a glance

  • Originator Capella Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain metastases

Most Recent Events

  • 06 Jan 2016 Preclinical trials in Brain metastases in USA (unspecified route)
  • 06 Jan 2016 Pharmacodynamics data from a preclinical study in brain metastases released by Capella Therapeutics
  • 06 Jan 2016 Capella Therapeutics plans a phase I trial for Brain metastases in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top